Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06945120 · ClinicalTrials.gov registry record · NA

ACT Lung Health Intervention: Phase Two

A NA study of Smoking Cessation and Smoking Behaviors, sponsored by Dana-Farber Cancer Institute.

Recruiting
Registry status
NA
Development phase
50
Enrollment target
2
Study locations

NCT06945120 is a NA study of Smoking Cessation and Smoking Behaviors that is actively recruiting participants, run by Dana-Farber Cancer Institute. The registered enrollment target is 50 participants, below the 474-participant average among 188 other Smoking Cessation trials with a reported enrollment target (89% lower). The trial reports 2 study locations across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06945120, a NA study of Smoking Cessation and Smoking Behaviors, is actively recruiting participants, sponsored by Dana-Farber Cancer Institute.

RECRUITING
Registry status
NA
Development phase
50 participants
Enrollment target
2
Study locations

Study Summary

This study aims to test a counseling and educational program designed to improve lung health through smoking cessation for Chinese and Korean American smokers at high risk for lung cancer.

Interventions

  • BEHAVIORAL ACT Lung Health Intervention

Study Locations (2)

Massachusetts

  • Dana-Farber Cancer Institute - Boston
  • University of Massachusetts-Boston - Boston

Trial Details

FieldValue
Enrollment Target 50 participants
Start Date 2025-11-04
Est. Completion 2026-12-31
Phase NA

Sponsor

Dana-Farber Cancer Institute

781 total trials

What the Registry Record Tells You About NCT06945120

The ClinicalTrials.gov registry entry for NCT06945120 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 474-participant average among 188 other Smoking Cessation trials with a reported enrollment target (89% lower). The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.

The record links to 5 conditions, with Smoking Cessation appearing as the primary indexed condition, and to 1 intervention - of which ACT Lung Health Intervention is the first listed.

NCT06945120 reports 2 study locations spanning 1 distinct geographic area - top geographies include Massachusetts.

Frequently Asked Questions

What is clinical trial NCT06945120 about?

NCT06945120 is a clinical study titled "ACT Lung Health Intervention: Phase Two". This study aims to test a counseling and educational program designed to improve lung health through smoking cessation for Chinese and Korean American smokers at high risk for lung cancer.

What is the current status of trial NCT06945120?

This trial is currently recruiting. It is a NA study. The enrollment target is 50 participants. The study started on 2025-11-04. Estimated completion is 2026-12-31.

What conditions does trial NCT06945120 study?

This clinical trial studies the following conditions: Smoking Cessation, Smoking Behaviors, Smoking, Cigarette, Smoking, Tobacco, Smoking (Tobacco) Addiction.

What interventions are being tested in trial NCT06945120?

The interventions under investigation include: ACT Lung Health Intervention (BEHAVIORAL).

Who is sponsoring clinical trial NCT06945120?

This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06945120 being conducted?

This trial has 2 study locations across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Smoking Cessation

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.